REGN vs SCL · P/E 14, rev $14.34B vs P/E 22, rev $2.18B
Regeneron Pharmaceuticals Inc (REGN) versus Stepan Company (SCL) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Stepan Company (SCL) is a specialty chemicals company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SCL revenue for 2024-12-31 was $2.18B. Net income was $50.4M. Revenue was down 6.3% from 2023-12-31 to 2024-12-31. SCL currently screens at market cap $1.29B and trailing P/E 22.3.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SCL currently screens at market cap $1.29B and trailing P/E 22.3.
Not investment advice. Open the REGN and SCL stock pages for the full models.
Not investment advice.